Business Description
Adial Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00688A2050
Total Employee Number:
6Description
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.71 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 65 | |||||
3-Year EPS without NRI Growth Rate | 64.6 | |||||
3-Year FCF Growth Rate | 67.4 | |||||
3-Year Book Growth Rate | -60.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 49.08 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.89 | |||||
9-Day RSI | 54.28 | |||||
14-Day RSI | 56.65 | |||||
3-1 Month Momentum % | 37.58 | |||||
6-1 Month Momentum % | -64.3 | |||||
12-1 Month Momentum % | -78.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.18 | |||||
Quick Ratio | 3.18 | |||||
Cash Ratio | 3.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -195.6 | |||||
Shareholder Yield % | -64.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -183.14 | |||||
ROA % | -139.7 | |||||
ROIC % | -619.69 | |||||
3-Year ROIIC % | -325.88 | |||||
ROCE % | -177.53 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.13 | |||||
Price-to-Tangible-Book | 1.12 | |||||
EV-to-EBIT | -0.2 | |||||
EV-to-EBITDA | -0.2 | |||||
EV-to-Forward-Revenue | 10151.48 | |||||
EV-to-FCF | -0.23 | |||||
| Price-to-Net-Current-Asset-Value | 1.27 | |||||
| Price-to-Net-Cash | 1.35 | |||||
Earnings Yield (Greenblatt) % | -500 | |||||
FCF Yield % | -107.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ADIL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adial Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -9.777 | ||
| Beta | 2.4164 | ||
| 3-Year Sharpe Ratio | -0.75 | ||
| 3-Year Sortino Ratio | -1.02 | ||
| Volatility % | 102.97 | ||
| 14-Day RSI | 56.65 | ||
| 14-Day ATR ($) | 0.280968 | ||
| 20-Day SMA ($) | 2.734 | ||
| 12-1 Month Momentum % | -78.93 | ||
| 52-Week Range ($) | 1.31 - 18.9 | ||
| Shares Outstanding (Mil) | 2.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adial Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adial Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 125 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 34 days | ||
| General meeting for 2026 | 2026-07-24 08:30 | In 14 days | ||
| Adial Pharmaceuticals Acquisition of Azora Therapeutics | 2026-06-11 01:00 | 2.16 (+2.37%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 1.42 (-11.93%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-06 | 1.97 (-0.51%) | ||
| Annual report for 2025 | 2026-03-05 | 1.99 (-11.95%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-25 14:40 | 2.44 (+3.39%) | ||
| 0.04:1 Stock Split | 2026-02-06 | 3.43 (-9.81%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 7.98 (-0.41%) |
Show
Entries
Adial Pharmaceuticals Inc Frequently Asked Questions
What is Adial Pharmaceuticals Inc(ADIL)'s stock price today?
The current price of ADIL is $2.76. The 52 week high of ADIL is $18.90 and 52 week low is $1.31.
When is next earnings date of Adial Pharmaceuticals Inc(ADIL)?
The next earnings date of Adial Pharmaceuticals Inc(ADIL) is 2026-08-14 Est..
Does Adial Pharmaceuticals Inc(ADIL) pay dividends? If so, how much?
Adial Pharmaceuticals Inc(ADIL) does not pay dividend.
Guru Commentaries on NAS:ADIL
No articles.
Press Release
Articles on Adial Pharmaceuticals Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers